CN104257761A - Pharmaceutical composition capable of decreasing blood sugar and pharmaceutical applications of pharmaceutical composition - Google Patents
Pharmaceutical composition capable of decreasing blood sugar and pharmaceutical applications of pharmaceutical composition Download PDFInfo
- Publication number
- CN104257761A CN104257761A CN201410521336.2A CN201410521336A CN104257761A CN 104257761 A CN104257761 A CN 104257761A CN 201410521336 A CN201410521336 A CN 201410521336A CN 104257761 A CN104257761 A CN 104257761A
- Authority
- CN
- China
- Prior art keywords
- extract
- pharmaceutical composition
- ethyl acetate
- syringae persicae
- flos syringae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The invention discloses a pharmaceutical composition capable of decreasing blood sugar and pharmaceutical applications of the pharmaceutical composition. The pharmaceutical composition comprises the following active ingredients: an extract from ethyl acetate of leptodermis ordosica, and the leptodermis ordosica is dried flower buds of oleaceae Syringa persica L. The pharmaceutical composition is orally administrated, and can reduce the blood sugar level of patients with hyperglycaemia, and has no effect on the blood sugar at normal level, and therefore, the pharmaceutical composition has no side effect such as hypoglycemia, and is applicable to patients with hyperglycaemia which is not developed into diabetes mellitus.
Description
Technical field
The invention belongs to technical field of extraction of Chinese traditional medicine, be specifically related to a kind of hypoglycemic pharmaceutical composition and pharmaceutical applications thereof.
Background technology
Sugar in blood of human body is called blood glucose, all glucose in most cases, sugar is one of requisite nutrition of human body, the energy major part of each histiocyte activity in human body is from glucose, corn, vegetable etc. that people take in, being converted into glucose through digestive system enters in blood, is transported to the cell of whole body, as the source of energy, so blood glucose must keep certain level could maintain the needs of each Organ and tissue.Normal person is 4.1-6.0mmol/L at fasting plasma glucose concentration, and fasting plasma glucose concentration is called hyperglycemia more than 6.0mmol/L, at this time can discharge along with urine by some glucose, diabetes that Here it is.
Diabetes are endocrine and metabolic disorders diseases of a kind of multi-pathogenesis.Along with the raising of people's living standard, the increase of aged tendency of population and fat incidence rate, the sickness rate of diabetes is in ascendant trend year by year.Show according to " diabetes mellitus in China control situation " report, China has become " severely afflicated area " of onset diabetes, and domestic at present have diabetics 30,000,000, is global diabetes second big country, and the trend in rejuvenation.If in the early stage of onset diabetes, just effectively can control diabetes, bring huge Gospel by diabetics, and be mostly the medicine for the treatment of diabetes in the market, rare prediabetes effectively controls the medicine of blood glucose.For the hyperglycemic patients not yet developing into diabetes, if take above-mentioned as Sulphonylurea, biguanides, glitazone antidiabetic drug, α-glucosides inhibitor etc., then very easily can there is hypoglycemia, be unfavorable for the rehabilitation of health on the contrary.
Summary of the invention
In view of the deficiencies in the prior art, the object of the invention is to by studying Chinese herbal medicine, thus a kind of hypoglycemic pharmaceutical composition and pharmaceutical applications thereof are provided, this pharmaceutical composition oral administration administration, the blood sugar level of hyperglycemic patients can be reduced, reducing effect is not had to the blood glucose of normal level, is applicable to the hyperglycemic patients not yet developing into diabetes.
In order to realize first object of the present invention, inventor, by lot of experiments research also persistent exploration, finally obtains following technical scheme:
A kind of hypoglycemic pharmaceutical composition, this pharmaceutical composition is prepared from by adjuvant acceptable on active component and pharmaceutics, wherein, active component in described pharmaceutical composition comprises the ethyl acetate extract extract of Flos syringae persicae, and described Flos syringae persicae is the dry flower of Oleaceae plants Persian lilac Syringa persica L..
It should be noted that, pharmaceutical composition of the present invention can be the peroral dosage form that this area is commonly used, as capsule (hard capsule, soft capsule), tablet (plain sheet, coated tablet, Film coated tablets), pill (micropill, drop pill), granule and tablet etc.Pharmaceutical composition of the present invention can directly use separately, also can form compound recipe with other medicines and use, can also use different pharmaceutic adjuvants, make many kinds of solids preparation or liquid preparation.Medicine of the present invention and compositions thereof use with the form of per weight dose, can oral or other form administration, carry out one or many use according to differences such as the type of age of route of administration, patient, body weight, institute's disease therapy and the orders of severity.
Preferably, hypoglycemic pharmaceutical composition as above, the active component in wherein said pharmaceutical composition is made up of as sole active agent the ethyl acetate extract extract of Flos syringae persicae.
Further preferably, hypoglycemic pharmaceutical composition described above, the ethyl acetate extract extract of wherein said Flos syringae persicae is prepared from as follows: be 90%-95% (v/v) alcohol reflux 1-3h by Flos syringae persicae concentration, filter, filtrate reduced in volume reclaims ethanol extremely without alcohol taste, the paste obtained adds distilled water and mixes loose, be extracted with ethyl acetate, the extract obtained is condensed into paste after reclaiming ethyl acetate, lyophilization, pulverize, sieve, obtain the ethyl acetate extract extract dry powder of Flos syringae persicae.
The present inventor is studied by the Intervention trial of research Flos syringae persicae extract to normal mouse and alloxan hyperglycemia mouse model, the ethyl acetate extract extract of result display Flos syringae persicae has no significant effect normal mouse blood sugar, but significantly can reduce the blood glucose value of alloxan hyperglycemia mouse model, this illustrates that the ethyl acetate extract extract of Flos syringae persicae significantly can reduce the blood glucose value of hyperglycemia mice, can be used for the cardiovascular disease such as treatment diabetes.Therefore, second object of the present invention is to provide a kind of pharmaceutical applications, and the ethyl acetate extract extract of namely above-mentioned Flos syringae persicae reduces the application in the medicine of hyperglycemic patients blood sugar level in preparation; Or the application of the ethyl acetate extract extract of above-mentioned Flos syringae persicae in the medicine of preparation treatment diabetes.
Compared with prior art, pharmaceutical composition oral administration of the present invention administration, can reduce the blood sugar level of hyperglycemic patients, does not have reducing effect to the blood glucose of normal level, therefore there will not be the side effect such as hypoglycemia after taking medicine, be applicable to the hyperglycemic patients not yet developing into diabetes.
Detailed description of the invention
Be below concrete preparation example and the animal experiment example of Flos syringae persicae extract involved in the present invention, technical scheme of the present invention is done and describes further, but protection scope of the present invention be not limited to this embodiment.It should be noted that, the Flos syringae persicae in each embodiment selects the dry flower of Oleaceae plants Persian lilac Syringa persica L..
The preparation of embodiment 1 Flos syringae persicae extract
Flos syringae persicae dry flower 800g, coarse powder is ground into FW135 type Chinese medicine grinder, the extraction element alcohol heating reflux be placed in round-bottomed flask extracts, be 95% (v/v) ethanol 8L reflux, extract, 2h by concentration, filter, obtain alcohol extract, repeat 2 times, merge alcohol extract, concentrating under reduced pressure reclaims ethanol extremely without alcohol taste, the paste obtained adds distilled water and mixes loose, with isopyknic extraction into ethyl acetate 3 times, the extract obtained is through reclaiming ethyl acetate, be condensed into paste, lyophilization, be ground into fine powder, cross 100 mesh sieves, obtain Flos syringae persicae extract dry powder.
Embodiment 2 Flos syringae persicae extract is to the activity research of normal mouse blood sugar
SPF level Kunming mouse 36, male and female half and half, weight 18-22g.All mices are divided into following three groups at random, and namely low, the high dose group of blank group, Flos syringae persicae extract, often organizes 12, male and female half and half.Blank group gavages equal-volume distilled water, and Flos syringae persicae extract is low, high dose group animal gives Flos syringae persicae extract dry powder prepared by embodiment 1 by 0.2ml/10g weight gavage, and dosage is respectively 50,150mg/kg, 1 time/d, continuous 3d.After last administration, water 10h is can't help in fasting, gets blood in mouse orbit venous plexus, by blood sugar detection test kit time-and-motion study blood glucose value.
The activity research of Flos syringae persicae extract to normal mouse blood sugar the results are shown in Table 1.Visible by the test statistics result of table 1, the blood glucose of low, the high dose group of Flos syringae persicae extract is compared with blank group, no significant difference (P > 0.05), this illustrates that Flos syringae persicae extract does not affect substantially on normal mouse blood sugar.
After table 1 administration, each group normal mouse blood glucose value compares
Embodiment 3 Flos syringae persicae extract is to the activity research of alloxan hyperglycemia mouse blood sugar
SPF level Kunming mouse 55, weight 18-22g.After water 24h is can't help in fasting, random taking-up 10 is only as outside Normal group, press the modeling of 220mg/kg body weight lumbar injection alloxan for all the other 45, after 72h, water 10h is can't help in mice fasting, then gets blood in mouse orbit venous plexus and survey blood glucose, select blood glucose value to be modeling success mice 30 mices of 8.8-30mmol/L, be divided into by blood sugar level that alloxan model control group, Flos syringae persicae extract are low, high dose group at random, often organize 10.Except Normal group and model control group gavage equal-volume distilled water, the Flos syringae persicae extract dry powder that Flos syringae persicae extract is low, high dose group animal gives embodiment 1 preparation by 0.2ml/10g weight gavage, dosage is respectively 50,150mg/kg, 1 time/d, continuous 3d.After last administration, water 10h is can't help in mice fasting, gets blood in orbital venous plexus, by blood sugar detection test kit time-and-motion study blood glucose value.
The impact of Flos syringae persicae extract on alloxan hyperglycemia mouse blood sugar the results are shown in Table 2.Can be found out by the result of the test of table 2, the blood glucose value respectively organized except Normal group before administration significantly rises, and this imply that the zoic model with hyperglycemia modeling success of setting up through alloxan.After administration, Flos syringae persicae extract is low, high dose group blood glucose value compares with alloxan model group, there is significant differences (P < 0.01) statistically, this illustrates that Flos syringae persicae extract significantly can reduce the blood glucose value of hyperglycemia mice, can be used for the cardiovascular disease such as treatment diabetes.
Before and after table 2 administration, each group alloxan hyperglycemia mouse blood sugar value compares
Compare with Normal group,
★p < 0.05,
★ ★p < 0.01; Compare with model control group,
p < 0.05,
p < 0.01.
Claims (5)
1. a hypoglycemic pharmaceutical composition, is characterized in that, the active component in described pharmaceutical composition comprises the ethyl acetate extract extract of Flos syringae persicae, and described Flos syringae persicae is the dry flower of Oleaceae plants Persian lilac Syringa persicaL..
2. hypoglycemic pharmaceutical composition according to claim 1, is characterized in that, the active component in described pharmaceutical composition is made up of as sole active agent the ethyl acetate extract extract of Flos syringae persicae.
3. hypoglycemic pharmaceutical composition according to claim 1 or 2, it is characterized in that, the ethyl acetate extract extract of described Flos syringae persicae is prepared from as follows: be 90%-95% (v/v) alcohol reflux 1-3h by Flos syringae persicae concentration, filter, filtrate reduced in volume reclaims ethanol extremely without alcohol taste, and the paste obtained adds distilled water and mixes loose, be extracted with ethyl acetate, the extract obtained is condensed into paste, lyophilization after reclaiming ethyl acetate, pulverizes.
4. the ethyl acetate extract extract of Flos syringae persicae according to claim 3 reduces the application in the medicine of hyperglycemic patients blood sugar level in preparation.
5. the application of the ethyl acetate extract extract of Flos syringae persicae according to claim 3 in the medicine of preparation treatment diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410521336.2A CN104257761A (en) | 2014-09-30 | 2014-09-30 | Pharmaceutical composition capable of decreasing blood sugar and pharmaceutical applications of pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410521336.2A CN104257761A (en) | 2014-09-30 | 2014-09-30 | Pharmaceutical composition capable of decreasing blood sugar and pharmaceutical applications of pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104257761A true CN104257761A (en) | 2015-01-07 |
Family
ID=52149418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410521336.2A Pending CN104257761A (en) | 2014-09-30 | 2014-09-30 | Pharmaceutical composition capable of decreasing blood sugar and pharmaceutical applications of pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104257761A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1879702A (en) * | 2005-06-15 | 2006-12-20 | 孙介光 | A medicine for preventing and treating diabetes, preparation method and application thereof |
| CN103141630A (en) * | 2013-02-20 | 2013-06-12 | 蓝照斓 | Bredia fordii health-care tea |
| CN103705826A (en) * | 2013-12-27 | 2014-04-09 | 孔庆玉 | Traditional Chinese medicine navel compressing agent for treating pediatric acute gastritis |
-
2014
- 2014-09-30 CN CN201410521336.2A patent/CN104257761A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1879702A (en) * | 2005-06-15 | 2006-12-20 | 孙介光 | A medicine for preventing and treating diabetes, preparation method and application thereof |
| CN103141630A (en) * | 2013-02-20 | 2013-06-12 | 蓝照斓 | Bredia fordii health-care tea |
| CN103705826A (en) * | 2013-12-27 | 2014-04-09 | 孔庆玉 | Traditional Chinese medicine navel compressing agent for treating pediatric acute gastritis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101607006B (en) | Application of Chinese medicinal composition in preparing medicament for treating hypertension | |
| CN101926865B (en) | Spina date seed depression-resolving and nerve-soothing composition and preparation method thereof | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| JP2002154979A (en) | Medicine composition for i type allergy and method for producing the same | |
| CN104042684B (en) | A kind of Chinese medicine composition containing Herb Gynostemmae Pentaphylli extract and preparation method | |
| CN104257761A (en) | Pharmaceutical composition capable of decreasing blood sugar and pharmaceutical applications of pharmaceutical composition | |
| CN101549070A (en) | Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular disease | |
| CN102145091B (en) | Traditional Chinese medicinal composition for eliminating wind and relieving heat and preparation method thereof | |
| CN107582866B (en) | Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension | |
| CN103768579A (en) | Traditional Chinese medicine for reducing blood sugar and preparation method thereof | |
| CN104055963B (en) | A kind of fat reducing Chinese medicine composition and preparation method | |
| CN102579947B (en) | Chinese medicinal composition and preparation method thereof | |
| CN102302545A (en) | Dai medicine extract with blood-sugar reducing activity, preparation method, composition and application | |
| WO2021063016A1 (en) | Composition with hypolipidemic function, preparation method therefor and application thereof | |
| CN101040905B (en) | Medicine made by selfheal for reducing blood sugar | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| CN100364553C (en) | Natural medicinal composition for preparing diabete drug | |
| CN104258034A (en) | Traditional Chinese medicine composition for boosting immunity | |
| CN104435079A (en) | Traditional Chinese medicinal composition for treating gout | |
| CN104208485A (en) | Pharmaceutical preparation for reducing blood sugar as well as preparation method and application of pharmaceutical preparation | |
| CN103768450B (en) | A kind of Chinese medicine composition and preparation method thereof, preparation and application | |
| CN102631486B (en) | Health care composition | |
| CN103505505A (en) | Blood lipid reducing composition containing ginkgo leaves and preparation method of composition | |
| CN104473957B (en) | A kind of Chinese medicine monomer compositions for blood fat reducing and preparation thereof | |
| CN105381362A (en) | Composition for preventing and treating alcoholic liver injury and relieving alcoholism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150107 |